Precigen: Entering The Oncology 'Sweet Spot'
Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen: Full Commercial Validation And Room To Run
Precigen is recommended as a buy due to PAPZIMEOS's early FDA approval, its commercial validation, and astonishingly quick insurer and physician adoption. PGEN's AdenoVerse platform underpins near-term growth, with PAPZIMEOS targeting a $2B global RRP market and PRGN-2009 advancing in other HPV-related cancer trials. Management projects a cash flow positive status in 2024, with consensus estimates showing sharply improving EPS and revenue through 2028 and beyond.
Precigen Q1 Earnings Call Highlights
Precigen NASDAQ: PGEN reported a sharp increase in first-quarter 2026 revenue as the company's first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.07 per share a year ago.
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
Precigen maintains a Buy rating as Papzimeos' strong launch and FDA approval signal blockbuster potential, with Q1 revenues expected to exceed $18M. PGEN's management guides for cash flow breakeven in 2026, supported by robust payer acceptance and a Q1 revenue run rate over $70M. Scenario analysis yields a probability-weighted fair value of $6.13/share, over 50% above current levels, with a base case fair value of $7.01/share.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.04 per share a year ago.
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
